

# Head and Neck Oncologic Surgery Fellowship Program

A Legacy of Leadership and Innovation



Memorial Sloan Kettering  
Cancer Center

# Training the Future Leaders of Cancer Care



## CONTENTS

History .....	2
Fellowship Program .....	4
Faculty.....	6
Recent Publications by MSK Head and Neck Surgery Fellows .....	32
Head and Neck Service Alumni .....	35

## HISTORY

For more than a century, the Head and Neck Service at Memorial Sloan Kettering Cancer Center has provided leadership and innovation in the field of head and neck surgery and oncology.



Memorial Sloan Kettering Cancer Center was founded in 1884 as New York Cancer Hospital on Manhattan's Upper West Side by a group that included John J. Astor and his wife, Charlotte.

The Head and Neck Service at Memorial Sloan Kettering Cancer Center was established in 1914 and was the first service dedicated to the care of patients with head and neck cancers. Dr. Henry Janeway was appointed the first Chief of the Head and Neck Service and was a pioneer in the use of radiation therapy for patients with head and neck tumors. After his retirement in 1921, his successor Dr. Douglas Quick, continued Dr. Janeway's work with radium x-rays and radon seeds.

In 1934, Dr. Hayes Martin, the "father" of head and neck surgery as we know it today, was appointed Chief. Dr. Martin popularized fine-needle aspiration biopsy as a diagnostic pre-treatment procedure and also developed new surgical procedures for treating head and neck tumors, including the "Commando Operation," a radical treatment for oral cancer that involves removal of part of the mandible as well as a neck dissection. In addition to his clinical accomplishments, Dr. Martin was a devoted teacher and mentor to residents and fellows. In 1954, Dr. Martin founded the Society of Head and Neck Surgeons, one of the parent organizations of the American Head and Neck Society.

After Dr. Martin's retirement in 1957, Dr. Edgar Frazell was appointed the service's chief. Dr. Frazell was an international leader in the diagnosis and treatment of thyroid cancers. He also served as the president of the Society of Head and Neck surgeons in 1966.

Dr. Elliot Strong joined the Head and Neck Service in 1963 and became its Chief in 1969. During his time in this position, Dr. Strong contributed to major advances in the field, including new treatments stemming from surgeons collaborating with radiation and medical oncologists. Dr. Strong also promoted immediate reconstruction of surgical defects following resection of the primary tumor using local and free flaps. The one-year clinical fellowship he established in 1979 is the model still in use today.

Dr. Jatin Shah was recruited to MSK in 1974. During his first years on the service, Dr. Shah introduced myocutaneous flaps and free jejunal flaps, which opened the door to additional microvascular reconstruction techniques, including the fibular free flap described by Dr. David Hidalgo. Dr. Shah became Chief in 1992.



Jatin Shah

By carefully selecting surgeons and recruiting them to the service, Dr. Shah created a team that would lead the field of head and neck cancer in both clinical and translational research. During his 23 years as Chief, Dr. Shah became a world leader in the field of head and neck cancer and the service continued to be a center of excellence in patient care, research, and education. In 2015, Dr. Shah stepped down as Chief to dedicate more time towards the education of the next generation of head and neck surgeons, both within MSK and internationally through the Online Head and Neck Fellowship Program of the International Federation of Head and Neck Oncologic Societies, both of which he founded.

In 2015, Dr. Richard Wong, an MSK trained surgeon, and scientist was appointed chief of the Head and Neck Service to continue the legacy of leadership and innovation for the benefit of head and neck cancer patients.

## Surgery

The Head and Neck Service cares for more than 3,172 new patients, performs approximately 1768 surgical procedures, and manages more than over 14,339 outpatient visits each year. As one of the largest referral centers in the world, MSK receives patients from the greater New York area, the United States, and around the globe.

With new cutting-edge diagnostic and therapeutic technologies, the Head and Neck service at MSK is always at the front. These include transoral robotic surgery (TORS), endoscopic skull base surgery and transoral laser microsurgery (TLM) for early laryngeal cancer.

## Disease Management Team (DMT)

Our integrated disease management team (DMT) consists of head and neck surgeons, plastic and reconstructive surgeons, neurosurgeons, medical oncologists, radiation oncologists, pathologists, radiologists, basic scientists, speech and voice therapists and dedicated nursing staff.

The Head and Neck DMT is leading wide variety novel translational studies and clinical trials defining the role of genomics, precision oncology, immunotherapy, molecular serum and salivary markers, resistance mechanisms, the tumor microenvironment, de-escalation of therapy for human papilloma virus associated cancers, proton beam radiation, and other factors in the management of head and neck cancers.



## FELLOWSHIP PROGRAM

### Overview

The Head and Neck Oncologic Surgery Fellowship Program at Memorial Sloan Kettering Cancer Center is one of the most comprehensive and competitive programs in the United States. The fellowship program is accredited by the Advanced Training Council of the American Head and Neck Society (AHNS) and is designed for graduates of residency programs in otolaryngology, general surgery, and plastic surgery who seek state-of-the-art training in head and neck oncologic surgery and a multidisciplinary approach in management of head and neck cancer patients. The fellows are selected through the AHNS computerized matching system every year. The candidates are ranked according to their career goals, past achievements, and an in-person interview. The program offers a one-year clinical fellowship, a two-year combined clinical and research fellowship, or a three-year program that includes a clinical year and two years of basic research supported by a T32 training grant from the National Institutes of Health.

### Clinical Training

The fellowship program provides intensive hands-on surgical training in complex ablative head and neck oncologic surgery and minimally invasive techniques. This includes composite resection of tumors of the oral cavity and oropharynx, craniofacial resection of sinonasal tumors, excision of advanced skin cancers, salivary gland tumors, early and advanced laryngeal and hypopharyngeal cancers, parapharyngeal space tumors, advanced thyroid cancers, Trans Oral Robotic Surgery (TORS), Transoral Laser Microsurgery (TLM), and endoscopic skull base surgery including trans-nasal approach to pituitary and other skull base tumors.

In recent years, the major components of our fellows' operative volume have been: 25% thyroid, 15% oral cavity, 15% neck dissection, 10% endoscopic/robotic, 10% complex cutaneous, 5-10% salivary, and 5-10% skull base. Local, regional and myocutaneous flaps and reconstruction are done by the head and neck service while microvascular free flap reconstruction is performed by the plastic surgery service.

Each year, Memorial Sloan Kettering diagnoses and treats more than 3,500 people with head and neck cancer. Our team includes more than 45 medical professionals who focus exclusively on these diseases.



The clinical rotation consists of a 12-month period wherein fellows are responsible for preoperative and postoperative patient care, and are involved in surgical operations under the direction of the attending surgeons. Each fellow performs 350-400 procedures during the year of clinical rotation. Fellows work with a multidisciplinary team of physicians and other professionals specializing in head and neck oncology to ensure the optimal treatment for each patient. Our integrated disease management team (DMT) consists of head and neck surgeons, plastic and reconstructive surgeons, neurosurgeons, medical oncologists, radiation oncologists, maxillofacial prosthodontists, pathologists, radiologists, basic scientists, speech and voice therapists and dedicated nursing staff. Fellows have 3 weeks of vacation time annually. There is full-time NP coverage for inpatients (3 NP's), 4 PA's assist in the OR, clinic, and with floor work, and fellows assist in the instruction of a full team of rotating residents from 4 local residency programs.

## Education

Didactic lectures and clinical case-based learning are emphasized during the fellowship. One key educational component is the tumor board. This is a multidisciplinary group in which complex medical decision-making takes place among the faculty through discussion of the literature and the expected risks, benefits, and alternatives of treatment.

Additional weekly lectures are given by the faculty on all subjects within head and neck surgical oncology. Fellows also gain experience by participating in outpatient clinics, rounds, lectures, seminars, journal club, and research conferences. Fellows have access to all conferences at Memorial Sloan Kettering Cancer Center.

There are currently approximately 50 formal conferences per year and 4-6 cancer-related lectures each week. Fellows may also enroll in various career enhancement programs at Weill Cornell Medical College and are invited to participate in external training activities that are organized by the Head and Neck Service, including a trans-oral endoscopic laser microsurgery course and the Current Concepts in Head and Neck Surgery course, both held annually. Fellows are also given an opportunity to supervise and instruct residents.

## Research Opportunities

There are ample opportunities to participate in clinical research during the 12 month clinical fellowship, and most of our fellows complete and publish clinical research manuscripts during their fellowship. MSK provides a research methodology course for surgical fellows at the beginning of each year. Our attending staff provide mentorship and guidance on research projects utilizing Head and Neck service databases, or national cancer registries, to answer clinical questions. Our service's outcomes researchers and research staff actively maintain databases for 6 types of cancer, comprising 7000 patients treated at MSK. Research support staff are available to assist fellows with the full range of research endeavors, from protocol submission, data management, analyses, and abstract/manuscript preparation.

We offer a dedicated research fellowship funded by an NIH T32 grant for fellows who seek additional training in laboratory and translational research, with opportunities to devote 2 years of full time effort with no clinical responsibilities, in fields such as cancer genetics, tumor immunology, molecular imaging, thyroid carcinogenesis, or experimental therapeutics.



## Richard J. Wong, MD, FACS

*Attending Surgeon*  
*Chief, Head and Neck Service*  
Memorial Sloan Kettering Cancer Center

*Professor of Otolaryngology*  
Weill Cornell Medical College

**Education:** MD, Harvard Medical School

**Residency:** Harvard Otolaryngology Residency Program

**Fellowship:** Memorial Sloan Kettering Cancer Center





Richard Wong is the Chief of the Head and Neck Service. He leads a team of eleven head and neck surgeons who have expertise and national reputations in all aspects of head and neck oncologic surgery, including robotic surgery, transoral laser microsurgery, and endoscopic skull base surgery. Dr. Wong is a co-director of the Head and Neck Disease Management Team, and promotes multi-disciplinary approaches to patient management with team members from Medical Oncology, Radiation Oncology, Endocrinology, Plastic Surgery, Dentistry, and Speech and Swallowing.

Dr. Wong is committed towards fellow and resident education and is the Principal Investigator on a Head and Neck Surgical Oncology T32 Training Grant from the National Institutes of Health. He has also trained numerous research fellows, many of whom have gone on to develop their own independent research programs. He serves as the site director for the Cornell/Columbia otolaryngology residency program and is actively involved in the training and evaluation of residents and clinical fellows.

Dr. Wong has particular expertise in the surgical removal of thyroid cancer, nodal metastases from thyroid cancer, and recurrent thyroid cancer. He also has a strong interest in treating all aspects of head and neck oncology, including oral cancer, salivary tumors, malignant melanoma, and a variety of other tumor types.

Dr. Wong is a scientist and the Principal Investigator of an R01 grant from the National Cancer Institute. His laboratory group explores the molecular and cellular mechanisms underlying cancer perineural invasion. Dr. Wong directs an NIH-funded research laboratory that seeks to elucidate the cellular and molecular mechanisms of perineural invasion. His group collaborates with investigators from the Sloan Kettering Institute in cell biology and infectious disease. Dr. Wong's research previously focused on investigating how replication-competent, genetically modified oncolytic viruses may be used for the therapy of solid tumors.

Dr. Wong's laboratory has been previously been funded by grants from the National Institute of Dental and Craniofacial Research, the American Society of Clinical Oncology, the American College of Surgeons, the American Head and Neck Society, and the Flight Attendant Medical Research Institute.

#### Selected Publications

Deborde S, Omelchenko T, Lyubchik A, Zhou Y, He S, McNamara WF, Chernichenko N, Lee SY, Barajas F, Chen CH, Bakst RL, Vakiani E, He S, Hall A, Wong RJ. Schwann cells induce cancer cell dispersion and invasion. *J Clin Invest.* 2016; 126:1538-54.

He S, Chen CH, Chernichenko N, et al. GFR $\alpha$ 1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. *Proc Natl Acad Sci.* 2014;111(19):E2008-17.

Gil Z, Cavel O, Kelly K, et al. Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. *J Natl Cancer Instit.* 2010;102:107-18.

He S, He S, Chen CH, Deborde S, Bakst RL, Chernichenko N, McNamara WF, Lee SY, Barajas F, Yu Z, Al-Ahmadie HA, Wong RJ. The chemokine (CCL-CCR2) signaling axis mediates perineural invasion. *Mol Cancer Res.* 2015;13:380-90.

Bakst RL, Lee N, He S, et al. Radiation impairs perineural invasion by modulating the nerve microenvironment. *PLoS One.* 2012;7:e39925.

Lin SF, Lin JD, Chou TC, Huang YY, Wong RJ. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. *PLoS One.* 2013;8:e7768.

Chen CH, Chen W Y, Lin SF, Wong RJ. Epithelial mesenchymal transition enhances response to oncolytic herpes viral therapy through nectin-1. *Hum Gene Ther.* 2014 [Epub ahead of print].

Yu Z, Li S, Brader P, et al. Oncolytic vaccinia viral therapy of squamous cell carcinoma. *Mol Cancer.* 2009;8:45.

Lin SF, Price DL, Chen CH, et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. *J Clin Endocrinol Metab.* 2008;93:4403-7.

Lin SF, Gao SP, Price DL, et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. *Clin Cancer Res.* 2008;14:1519-28.

Yu Z, Adusumilli P, Eisenberg DP, et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. *Mol Ther.* 2007;15:103-13.

Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of [(18)F]Fj fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. *J Clin Oncol.* 2002;20:4199-208.




## Jay O. Boyle, MD, FACS

*Attending Surgeon*  
Memorial Sloan Kettering Cancer Center  
*Professor of Clinical Otolaryngology*  
Weill Cornell Medical College

**Education:** MD, University of Arizona College of Medicine

**Residency:** The Johns Hopkins Hospital

**Fellowship:** Memorial Sloan Kettering Cancer  
University of Arizona Cancer Center



### Selected Publications

Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. *Cancer Res.* 1993;53:4477-80.

Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. *N Engl J Med* 1995;332:712-7.

Boyle JO, Langenfeld J, Lonardo F, et al. Cyclin D1 repression is a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. *J Natl Cancer Inst.* 1999;91:373-9.

Boyle JO, Lonardo F, Chang JH, Klimstra D, Rusch V, Dmitrovsky E. Multiple high-grade bronchial dysplasia and squamous cell carcinoma: concordant and discordant mutations. *Clin Cancer Res.* 2001;7:259-66.

Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. *Cancer Res.* 2005;65:664-70.

Gross ND, Boyle JO, Du B, et al. Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma. *Clin Cancer Res.* 2007;13:5910-7.

Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. *Clinical Cancer Res.* 2008;14:2095-101.

Gümüş ZH, Du B, Kacker A, et al. Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. *Cancer Prev Res (Phila).* 2008;1:100-11.

Duffield-Lillico AJ, Boyle JO, Zhou XK, et al. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. *Cancer Prev Res (Phila).* 2009;2:322-9.

Dr. Boyle joined MSK in 1999 and was named Director of the fellowship training program in 2002-2016. Dr. Boyle has collaborated with Dr. Andrew Dannenberg to study carcinogenesis and prevention of tobacco smoke-related cancers. Together with more than a dozen head and neck fellows who trained with them over a 15-year period, they translated many important findings into clinical trials for cancer prevention. Dr. Boyle received NIH grants to study the efficacy of Cox-2 inhibitors and NSAIDs in oral leukoplakia. He has collaborated with investigators around the country and the world to study the prevention of cancer with EGFR inhibitors and PPAR gamma ligands.

Dr. Boyle has served on the executive council of the American Head and Neck Society as Research Committee Chair and Program Chair and on the executive council of the International Academy of Oral Oncology. He is the current president of the New York Head and Neck Society.



## Marc A. Cohen, MD, MPH

*Associate Attending Surgeon*  
Memorial Sloan Kettering Cancer Center  
*Assistant Professor of Otolaryngology*  
Weill Cornell Medical College

**Education:** MD, University of Pennsylvania  
MPH, Columbia University

**Residency:** Hospital of the University of Pennsylvania

**Fellowship:** Princess Margaret Cancer Centre, Toronto General Hospital



Marc Cohen is a head and neck cancer and skull base surgeon who specializes in caring for people with cancerous and noncancerous tumors of the head and neck and skull base. The diseases he treats as part of the multidisciplinary skull base tumor team include skull base tumors such as sinus cancers, pituitary adenomas (tumors of the pituitary gland), meningiomas and craniopharyngiomas (brain tumors), and chordomas (tumors of the bones of the skull and spine). In addition, Dr. Cohen treats patients with head and neck and thyroid cancer. As part of the MSK team, he works to use minimally invasive surgical techniques whenever possible.

Dr. Cohen's research focuses on patients' outcomes after treatment for head and neck and skull base tumors. He is specifically interested in studying quality of life following minimally invasive and endoscopic surgeries, focusing on cancer treatments that offer the potential for the fewest possible side effects.

#### Selected Publications

Cracchiolo JR, Roman BR, Kutler DI, Kuhel WI, **Cohen MA**. Adoption of Transoral Robotic Surgery Compared With Other Surgical Modalities For Treatment of Oropharyngeal Squamous Cell Carcinoma. *J Surg Oncol* 2016; 114:405-11.

Patel SN, Cohen MA, Givi B, Dixon BJ, Gilbert RW, Gullane PJ, Brown DH, Irish JC, de Almeida JR, Higgins KM, Enepekides D, Huang SH, Waldron J, O'Sullivan B, Xu W, Su S, Goldstein DP. Salvage Surgery of Locally Recurrent Oropharyngeal Cancer. *Head Neck* 2016;38:658-64.

Quon H, Cohen MA, Montone K, O'Malley BW Jr, Weinstein GS. Transoral Robotic Surgery (TORS) and Adjuvant Therapy for Oropharyngeal Carcinomas and the Influence of p16INK4a on Treatment Outcomes. *Laryngoscope* 2013; 123:635-40.

Cohen MA, Weinstein GS, O'Malley BW Jr, Feldman M, Quon H. Transoral Robotic Surgery (TORS) and Human Papillomavirus (HPV) Status: Oncologic Results. *Head Neck* 2011; 33:573-80.

Weinstein GS\*, O'Malley BW Jr\*, Cohen MA\*, Quon H\*. Transoral Robotic Surgery (TORS) for Advanced Oropharyngeal Carcinoma. *Arch Otolaryngol Head Neck Surg* 2010; 136:1079-85.

Weinstein GS, Quon H, O'Malley BW Jr, Kim GG, Cohen MA. Selective Neck Dissection and Deintensified Postoperative Radiation and Chemotherapy for Oropharyngeal Cancer: A Subset Analysis of the University of Pennsylvania Transoral Robotic Surgery Trial. *Laryngoscope* 2010; 120:1749-55.

Keefe SM, Cohen MA, Brose MS. Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications. *Clin Cancer Res* 2010;16(3):778-83.

Gabel BC\*, Cohen MA\*, Heuer GG, Pisapia J, Bohman LE, Leibowitz JM, O'Malley BW Jr., Grady MS. Comparison of Endoscopic and Microscopic Removal of Pituitary Adenomas: Single Surgeon Experience and the Learning Curve. *Neurosurg Focus* 2008; 25:E10.

Cohen MA, Liang J, Cohen IJ, Grady MS, O'Malley BW Jr., Newman JG. Endoscopic Resection of Advanced Stage Anterior Skull Base Lesions: Oncologically Safe? *ORL J Otorhinolaryngol Relat Spec* 2009; 71:123-8.

Cohen MA, Basha SB, Sewell DA. Increased Viral Load Correlates With Improved Survival in HPV-16 Associated Tonsil Carcinoma. *Acta Otolaryngol* 2008; 128:583.



## Jennifer R. Cracchiolo, MD

*Assistant Attending Surgeon*  
Memorial Sloan Kettering Cancer Center

*Assistant Professor of Otolaryngology*  
Weill Cornell Medical College

**Education:** MD, University of South Florida College of Medicine

**Residency:** Otolaryngology Head and Neck Surgery, Temple University Hospital

**Fellowship:** Head and Neck Surgical Oncology, Memorial Sloan Kettering Cancer Center



Jennifer Cracchiolo is a head and neck surgeon who has extensive experience in using minimally invasive techniques to provide my patients with the best possible functional and cosmetic outcomes. While her top priority is to treat and cure these diseases, she is also committed to helping her patients maintain their quality of life. She works closely with a team of world-renowned experts in radiation oncology, medical oncology, reconstructive surgery, molecular biology, and immunology to provide her patients with options that will help them look and feel like themselves before, during, and after their treatment.

Dr. Cracchiolo is leading the development of MSK's head and neck patient-reported outcomes program. This involves asking patients specific questions about their surgical experience, which in turn, helps MSK provide more personalized care based on what is most important to them. The Head and Neck patients at MSK are at the center of everything we do, and this program helps ensure they are provided with the best care possible.

#### Selected Publications

Cracchiolo JR, Xu B, Migliacci JC, Katabi N, Pfister DG, Lee NY, Patel SG, Ghossein RA, Wong RJ. Patterns of recurrence in oral tongue cancer with perineural invasion. *Head Neck*.

Cracchiolo JR, Wong RJ. Management of the lateral neck in well differentiated thyroid cancer. *Eur J Surg Oncol*. 2018;44(3):332-337.

Sayed Z, Migliacci JC, Cracchiolo JR, Barker CA, Lee NY, McBride SM, Tabar VS, Ganly I, Patel SG, Morris LT, Roman BR, Shoushtari AN, Cohen MA. Association of surgical approach and margin status with oncologic outcomes following gross total resection for sinonasal melanoma. *JAMA Otolaryngol Head Neck Surg*. 2017 143(12):1220-1227.

Cracchiolo JR, Patel K, Migliacci JC, Morris LT, Ganly I, Roman BR, McBride SM, Tabar VS, Cohen MA. Factors associated with a primary surgical approach for sinonasal squamous cell carcinoma. *J Surg Oncol*.

Roman BR, Baxi SS, Cracchiolo JR, Blackwell TJ, Pfister DG, McBride S, Ganly I, Shah JP, Patel SG, Morris LG, Cohen MA. Variation in use of postoperative chemoradiation following surgery for T1 and T2 oropharyngeal squamous cell carcinoma; National Cancer Database. *J Surg Oncol*. 2017 116(3):351-358.

Cracchiolo JR, Roman BR, Kutler DI, Kuhel WI, Cohen MA. Adoption of transoral robotic surgery compared with other surgical modalities for treatment of oropharyngeal squamous cell carcinoma. *J Surg Oncol*. 2016 Sep;114(4):405-411.

Cracchiolo JR, Baxi SS, Morris LG, Ganly I, Patel SG, Cohen MA, Roman BR. Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. *Cancer*. 2016;122(10):1523-1532.

Cracchiolo JR, Shaha AR. Parotidectomy for parotid cancer. *Otolaryngol Clin North Am*. 2016 49(2):415-424.

Linkov G, Cracchiolo JR, Chan NJ, Healy M, Jamal N, Soliman AMS. The role of serial physical examinations in the management of angioedema involving the head and neck: A prospective observational study. *World J Otorhinolaryngol Head Neck Surg*. 2016;2(1):7-12.

Norman ZI, Cracchiolo JR, Allen SH, Soliman AM. Auricular reconstruction after human bite amputation using the Baudet technique. *Ann Otol Rhinol Laryngol*. 2015;124(1):45-48.

Cracchiolo JR. Can we be as good as our mentors? *Ear Nose Throat J*. 2014;93(10-11):447-448.



## Ian Ganly, MD, PhD, MSc, FRCS(GIs,Ed), FRCS-ORL(Ed)

*Attending Surgeon*  
Memorial Sloan Kettering Cancer Center  
*Associate Professor of Otolaryngology*  
Weill Cornell Medical College

**Education:** MD, University of Glasgow  
PhD, University of Glasgow  
MSc, Columbia University

**Residency:** West of Scotland NHS Teaching Hospitals

**Fellowship:** Royal College of Physicians and Surgeons, Glasgow FRCS(GIs)  
Royal College of Surgeons, Edinburgh FRCS(Ed)  
Memorial Sloan Kettering Cancer Center





Ian Ganly was a clinical fellow at MSK from 2003 to 2005, during which time he was awarded the prestigious Michael E. Burt Fellow of the Year award for outstanding surgical excellence. Following his fellowship, he returned to his native Scotland, where he was an Attending Head and Neck Surgeon at the University of Edinburgh from 2005 to 2008. In 2008 he returned to MSK to take up his current position in the Head and Neck Service. Dr. Ganly has had fellowships in general surgery and otolaryngology–head and neck surgery from the Royal College of Surgeons, Edinburgh. He also has a PhD in molecular oncology from the University of Glasgow. Recently he was awarded an MSc in biostatistics and clinical research methods from the Mailman School of Public Health, Columbia University, New York.

His surgical interests are in thyroid surgery, skull base surgery, and minimally invasive surgery with trans-oral endoscopic laser and robotic surgery. His clinical research has largely focused on outcomes based on the development and analysis of large databases on thyroid cancer, salivary gland cancer, and oral cavity and oropharyngeal cancer. He also has strong interests in translational research focused on the application of genomics in thyroid and head and neck cancer. He collaborates with Dr. Timothy Chan and Dr. James Fagin at the Human Oncology Pathogenesis Program at MSK on these projects. He has been the principal investigator for MSK for the Cancer Genome Atlas thyroid cancer project and was responsible for the identification and recruitment of the thyroid cancer patients who participated in this study. He is currently carrying out genomics projects on Hurthle cell cancer and poorly differentiated thyroid cancer to identify the pathways involved in the pathogenesis of these cancers and identify potential targets for treatment

#### Selected Publications

Landa I, Ibrahimasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. *J Clin Invest*. 2016 Mar 1;126(3):1052-66.

Ganly I, Ibrahimasic T, Rivera M, et al. Prognostic implications of papillary thyroid carcinoma with tall cell features. *Thyroid*. 2014;24:662-70.

Ali S, Palmer FL, Yu C, Dilorenzo M, Shah JP, Kattan MW, Patel SG, Ganly I. Postoperative nomograms predictive of survival after surgical management of malignant tumors of the major salivary glands. *Ann Surg Oncol*. 2014;21:637-42.

Landa I, Ganly I, Chan TA, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. *J Clin Endocrinol Metab*. 2013;98:E1562-6.

Ganly I, Ricarte Filho J, Eng S, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. *J Clin Endocrinol Metab*. 2013;98:E962-72.

Ibrahimasic T, Ghossein R Md, Carlson DL, Chernichenko N, Nixon I, Palmer FL, Lee NY, Shaha AR Md, Patel SG, Tuttle RM Md, Balm AJ, Shah JP, Ganly I. Poorly differentiated thyroid carcinoma presenting with gross extrathyroidal extension: 1986-2009 Memorial Sloan Kettering Cancer Center experience. *Thyroid*. 2013;23:997-1002.

Ganly I, Goldstein D, Carlson DL, et al. Long-term regional control and survival in patients with "low-risk," early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumor thickness. *Cancer*. 2013;119:1168-76.

Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. *Cancer*. 2011;117:4439-46.

Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. *J Clin Oncol*. 2011;29:739-46.

Ganly I, Talbot S, Carlson D, et al. Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. *J Clin Oncol*. 2007;25:1369-76.



## Luc Morris, MD, MSc, FACS


*Associate Attending Surgeon  
Catherine and Frederick J. Adler Chair for Junior Faculty  
Director, Fellowship Training Program in Head and Neck Surgery  
Memorial Sloan Kettering Cancer Center*

*Associate Professor of Otolaryngology  
Weill Cornell Medical College*

**Education:** MD, New York University School of Medicine  
MSc, Columbia University

**Residency:** NYU Medical Center

**Fellowship:** Memorial Sloan Kettering Cancer Center



Luc Morris is an Associate Attending Surgeon on the Head and Neck Service and holds an Adlerian Junior Faculty Chair at MSK. Dr. Morris was appointed fellowship director in 2016. Luc grew up in Northern California, and attended Brown University, New York University School of Medicine, and Columbia University. After residency at NYU, he was a head and neck surgery fellow at MSK. He has clinical expertise in transoral laser microsurgery (TLM) for laryngeal and oropharyngeal tumors, and in the incorporation of these technologies into the broader landscape of evolving multidisciplinary therapies. He also heads an NIH-funded laboratory research group focused on cancer genomics as applied to squamous cell and salivary tumors, and an epidemiologic research program studying thyroid cancer overdiagnosis and overtreatment.

#### Selected Books

Luc GT Morris and Jatin P Shah. Technical Refinements in Head and Neck Surgery. Philadelphia: *JP Medical*, 2014.

#### Selected Publications

Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papilloma virus-associated oropharyngeal cancer. *J Clin Oncol*. 2011;29:739-46.

Morris LG, Taylor BS, Bivona T, et al. Genomic dissection of the EGFR/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. *Proc Natl Acad Sci U S A*. 2011;108:19024-9.

Morris LG, Kaufman AM, Gong Y, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. *Nat Genet*. 2013;45:253-61.

Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. *Thyroid*. 2014;23:885-91.

Morris LG, Riaz N, Desrichard A, Senbaboglu Y, Hakimi A, Makarov V, Reis-Filho JS, Chan TA. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. *Oncotarget* 2016;7:10051-63.

Morris LG, Tuttle RM, Davies L. Changing trends in the incidence of thyroid cancer in the United States. *JAMA Otolaryngology* 2016 [Epub]

Morris LG, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS, Ganly I, Singh B, Shah JP, Shaha AR, Boyle JO, Patel SG, Roman BR, Barker CA, McBride SM, Chan TA, Dogan S, Hyman DM, Berger MF, Solit DB, Riaz N, Ho AL. The distinct molecular landscape of recurrent and metastatic head and neck cancers unveiled by a precision oncology sequencing platform. *JAMA Oncology* 2016 [Epub]

Dalin M, Desrichard AD, Katabi N, Makarov V, Walsh LA, Lee KW, Wang Q, Armenia J, West L, Dogan S, Wang L, Ramaswami D, Ho AL, Ganly I, Solit DB, Berger MF, Schultz ND, Reis-Filho JS, Chan TA, Morris LG. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. *Clinical Cancer Research* 2016 [Epub]



## Snehal G. Patel, MD, MS, FRCS

*Attending Surgeon*  
Memorial Sloan Kettering Cancer Center

*Professor of Otolaryngology*  
Weill Cornell Medical College

**Education:** MD, Shree Sayaji General Hospital & Medical College,  
Maharaja Sayajiro University of Baroda

**Residency:** Shree Sayaji General Hospital & Medical College

**Fellowships:** Tata Memorial Hospital, The Royal Marsden Hospital,  
Memorial Sloan Kettering Cancer Center



Snehal Patel is working to improve care of people with head and neck cancers with a multipronged research program that includes development of new technology for in vivo imaging and minimally invasive treatment of tumors; evaluation of patient expectations and development of novel patient education techniques; development of statistical methods for predicting individualized outcomes; and assessment of quality of care, patient satisfaction, and quality of life. He holds a US patent for a novel endoscopic laser-steering device that is currently being developed for minimally invasive surgical applications. His research efforts have been funded by intra- and extramural grants totaling over \$1.5 million. He currently leads clinical trials at MSKCC using Targeted Silica Nanoparticles for Image-Guided Sentinel Lymph Node Mapping for Patients with Melanoma of the Head and Neck, Imaging Oral Cancer In Vivo using Confocal Reflectance Microscopy, and PARP1 based Intra-operative Imaging of Cancer of the Oral Cavity

#### Selected Publications

Zanoni DK, Migliacci JC, Xu B, et al. A Proposal to Redefine Close Surgical Margins in Squamous Cell Carcinoma of the Oral Tongue. *JAMA Otolaryngol Head Neck Surg.* 2017

Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 2017 Mar;67(2):122-137.

Wreesmann VB, Katabi N, Palmer FL, et al. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. *Head Neck.* 2016 Apr;38 Suppl 1:E1192-9.

Montero PH, Palmer FL, Shuman AG, et al. A novel tumor: specimen index for assessing adequacy of resection in early stage oral tongue cancer. *Oral Oncol.* 2014;50:213-20.

Montero PH, Yu C, Palmer FL, et al. Nomograms for preoperative prediction of prognosis in patients with oral cavity squamous cell carcinoma. *Cancer.* 2014;120:214-21.

Bradbury M, Phillips E, Montero Miranda P, et al. Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. *Integr Biol (Camb).* 2013;5:74-86.

Nixon IJ, Ganly I, Hann LE, et al. Nomogram for predicting malignancy in thyroid nodules using clinical, biochemical, ultrasonographic, and cytologic features. *Surgery.* 2010;148:1120-7; discussion 1127-8.

Gil Z, Carlson DL, Boyle JO, et al. Lymph node density is a significant predictor of outcome in patients with oral cancer. *Cancer.* 2009;115:5700-10.

Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. *CA Cancer J Clin.* 2005;55:242-58.

Patel SG, Singh B, Polluri A, et al. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. *Cancer.* 2003;98:1179-87.

Patel SG, Meyers P, Huvos AG, et al. Improved outcomes in osteogenic sarcoma of the head and neck. *Cancer.* 2002;95:1495-503.

Patel SG, Escrig M, Prasad M, et al. Primary malignant mucosal melanoma of head and neck. *Head Neck.* 2002;24:247-57.

Patel SG, See ACH, Williamson PA, Archer DJ, Rhys Evans PH. Radiation induced sarcoma of the head and neck. *Head Neck.* 1999;21:346-54.



## Benjamin Roman, MD, MSHP

*Assistant Attending Surgeon*  
Memorial Sloan Kettering Cancer Center

*Assistant Professor of Otolaryngology*  
Weill Cornell Medical College

**Education:** MD, Mount Sinai School of Medicine  
MSHP, University of Pennsylvania School of Medicine

**Residency:** NYU Medical Center

**Fellowship:** Memorial Sloan Kettering Cancer Center  
University of Pennsylvania School of Medicine  
Robert Wood Johnson Clinical Scholars Program



Benjamin Roman is a head and neck surgeon and health services researcher. Clinically, he specializes in the treatment of head and neck cancers, thyroid cancer, and skin cancer. Dr. Roman takes a team approach with his colleagues, focused on choosing individualized treatments to achieve the best outcomes.

Health services research in general aims to develop innovative ways to ensure the highest-quality and highest-value care so that patients can return to their lives as quickly as possible. Dr. Roman's research in healthcare delivery is based on this desire to individualize and improve treatment decisions. He takes pride in helping his patients navigate decisions regarding their cancer treatment and quality of life after treatment, based on the things that really matter to them.

#### Selected Publications

Wang, L. Y., Roman, B. R., Migliacci, J. C., Palmer, F. L., Tuttle, R. M., Shaha, A. R., & Ganly, I. Cost-effectiveness analysis of papillary thyroid cancer surveillance. *Cancer*. 2015, 121(23):4132-40.

Marti, J. L., Davies, L., Haymart, M. R., Roman, B. R., Tuttle, R. M., & Morris, L. G. Inappropriate use of radioactive iodine for low-risk papillary thyroid cancer is most common in regions with poor access to healthcare. *Thyroid*. 2015, 25(7):865-6.

Roman, B. R., Goldenberg, D., & Givi, B. Guideline recommended follow-up and surveillance of head and neck cancer survivors. *Head and Neck*. 2015, 38(2):168-74.

Roman, B. R. On marginal health care-probability inflation and the tragedy of the commons. *N Engl J Med*. 2015, 372(6):572-5.

Roman, B. R., Patel, S. G., Wang, M. B., Pou, A. M., Holsinger, F. C., Mysiorek, D., & Shea, J. A. Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer. *J Natl Compr Canc Netw*. 2015, 13(1):69-77.

Roman, B. R., Feingold, J. H., Patel, S. G., Shaha, A. R., Shah, J. P., Tuttle, R. M., & Epstein, A. J. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1cm. *Thyroid*. 2014, 24(10):1549-50.

Roman, B. R., Awad, M. I., & Patel, S. G. Defining value-driven care in head and neck oncology. *Curr Oncol Rep*. 2015, 17(1):424.

Roman, B. R., & Feingold, J. Patient-centered guideline development: best practices can improve the quality and impact of guidelines. *Otolaryngol Head Neck Surg*. 2014, 151(4):530-2.

Roman, B. R., & Asch, D. A. (2014). Faded promises: the challenge of deadopting low-value care. *Ann Intern Med*. 2014, 161(2):149-50.



## Jatin Shah, MD

*Senior Attending Surgeon  
Elliot W. Strong Chair in Head and Neck Oncology  
Memorial Sloan Kettering Cancer Center*

*Professor of Surgery  
Weill Cornell Medical College*

**Education:** MD, Medical College, MS University, Baroda (India)

**Residency:** New York Infirmary

**Fellowship:** Memorial Sloan Kettering Cancer Center  
Diplomate, American Board of Surgery





Jatin Shah has extensive experience and expertise in all aspects of head and neck surgery, including skull base and sinus surgery, salivary and thyroid tumors, and tumors of the oral cavity, pharynx, larynx, and trachea. He has developed, devised and revised many new surgical procedures for access and resection at the skull base and for laryngo-tracheal and mediastinal tumors, with the goal to preserve organ function and facial appearance to a far greater degree than was previously possible. His technical expertise is known worldwide.

Dr. Shah has been actively involved in training the next generation of hundreds of head and neck cancer surgeons for the past four decades. Under his leadership, the MSK fellowship program, grew from 2 to

eight fellows supported by an NIH T32 grant since 1992. The fellowship program draws talented surgeons to MSK from all over the world as fellows or observers. In addition, Dr. Shah has developed the unique Global Online Fellowship program, from which nearly 200 surgeons from 49 countries are currently receiving training.

In addition to his clinical, teaching, training, and research activities at MSK, Dr. Shah is an internationally recognized leader who has served as president of the Society of Head and Neck Surgeons, the North American Skull Base Society, the New York Head and Neck Society, the New York Cancer Society, and the International Academy of Oral Oncology. He founded the International Federation of Head and Neck Oncologic Societies (IFHNOS) and serves as its Chief Executive Officer. The award-winning textbooks written by him are state-of-the-art resources in head and neck surgery. He has been awarded Honorary Fellowships from the Royal Colleges of Surgeons of England, Edinburgh, Ireland and Australia, and has received Honorary PhD degrees from Belgium and Greece, as well as an Honorary DSc from India. He is recipient of the Blokhin Gold Medal from Russia, Janeway Medal from the American Radium Society and the Ellis Island Medal of Honor. Amongst his numerous awards and Honorary Memberships in scientific societies all over the world, he has received Life Time achievement awards from scientific societies from all five continents in the world. Over the years, he has also served in varying capacities on the American Board of Surgery, the Commission on Cancer of the American College of Surgeons, as Chairman of the Advanced Training Council for Head and Neck Surgery as well as Chairman of the Head and Neck task force of the American Joint Committee on Cancer. He has authored 11 books, 82 chapters, and over 550 peer reviewed publications. He has delivered over 1600 scientific presentations and 90 eponymous lectures. In recognition of his extraordinary contributions and achievements in Head and Neck Surgery, the IFHNOS has established the Jatin Shah Lecture at its world congresses, The American Head and Neck Society has established an Annual symposium in his name, and MSK has established the Jatin P Shah, endowed Chair in Head and Neck Surgery.

#### **Selected Books**

Jatin Shah's Head and Neck Surgery and Oncology. 4th ed. Shah JP, Patel SG, Singh B, eds. Philadelphia: Elsevier; 2012.

Oral Cancer. Shah JP, Johnson NW, Batsakis JG, eds. London: Martin Dunitz; 2003.

Cancer of the Head and Neck. Shah JP, ed. Toronto: BC Decker; 2001.

Essentials of Head and Neck Oncology. Close LG, Larson DL, Shah JP, eds. New York: Thieme; 1998.

#### **Selected Publications**

Shah JP. Patterns of nodal metastases from squamous carcinomas of the upper aerodigestive tract. *Am J Surg* 1990, 160:405-409.

Shah JP and Ihde J. Salivary Gland Tumors. *Curr Prob Surg*, 1990, 27:772-883.

Shah JP. The making of a head and neck surgeon. *Am J Surg*, 1991, 162:284-287.

Shah JP, Loree T, Dharkar D, and Strong EW. Prognostic factors in differentiated carcinoma of the thyroid. *Am J Surg*. 1992, 164:658-661.

Shah JP and Andersen PE. The impact of patterns of neck metastasis on modifications of neck dissection. *Ann Surg Onc* 1994;1:521-532.

Shah JP. The Making of a Specialty. *Am J Surg*, 1998, 176:398-403.

Patel SG, Singh B, Polluri A, Bridger PG, Cantu G, Cheesman AD, deSa GM, Donald P, Fliss D, Gullane P, Janecka I, Kamata S, Kowalski LP, Kraus DH, Levine PA, dos Santos LRM, Pradhan S, Schramm V, Snyderman C, Wei WJ, Shah JP. Craniofacial surgery for malignant skull base tumors: Report of an international collaborative study. *Cancer* 2003 Sept 15; 98(6):1179-87.

Shah JP. Head and Neck Surgery in crisis: Preparing for the future. Commentary. *Arch. Otol Head Neck Surg*. 2005, July, 131:556-560.



## Ashok Shaha, MD, FACS

*Attending Surgeon*  
*Jatin P. Shah Chair in Head and Neck Surgery*  
Memorial Sloan Kettering Cancer Center

*Professor of Surgery*  
Weill Cornell Medical College

**Education:** Medical College, University of Baroda (India)

**Residency:** SUNY Downstate Medical Center

**Fellowship:** Memorial Sloan Kettering Cancer Center



Dr. Shaha completed his surgical training in India and at Downstate Medical Center in Brooklyn. He did his Surgical Oncology and Head and Neck Fellowship at Memorial Hospital. He joined the Department of Surgery at Downstate Medical Center, rising to the rank of Professor of Surgery in 1992. During this period, he was also Chief of Head and Neck Surgery at King's County, Brooklyn VA Hospital and University Hospital. In August of 1993, Dr. Shaha moved to Sloan Kettering.

He received the Golden Apple Teaching Award at Downstate. Other awards - Faculty Member of the AOA, the Outstanding Teacher Award at MSK, the Honor Award and Distinguished Service Award from the AAO-HNS. He was President of the New York Head and Neck Society, the American Society for Surgeons of Indian Origin, and the Brooklyn Surgical Society. He was Co-President of the American Head and Neck Society, 1999 and was President of the New York Cancer Society and New York Surgical Society. He serves on the editorial board of the Journal of Surgical Oncology, Head and Neck, Annals of Surgical Oncology, Brazilian Journal of Surgery, and Journal of Clinical Oncology. He is an honorary member of the Brazilian College of Surgeons, the Cuban Surgical Society, Association of Surgeons of India, the Korean Head and Neck Society, Latin Head and Neck Society, Panamanian Society of Oncology, Chilean College of Surgeons, and Costa Rican Endocrine Society. He was the Program Chairman of the Fifth International Head and Neck Oncology Meeting in San Francisco (2000) and served as the Conference Chairman for the Sixth International Head and Neck Meeting in 2004. He was President of the American Association of Endocrine Surgeons. Recently he was elected to the American Surgical Association. In July 2016, he delivered the Hayes Martin Lecture. For the past four years he has been Director of International Federation of Head and Neck Societies and has traveled twice for IFHNOS World Tour.

Dr. Shaha has published 650 papers, 515 of which are peer-reviewed. His Curriculum Vitae includes 150 published abstracts, 63 posters and 45 scientific exhibits. His research interests include tracheal reconstruction and an experimental model of tracheomalacia and thyroid cancer.

Dr. Shaha has dedicated his professional career to the training of medical students and residents and has developed a preceptorship program at Cornell University Medical College in head and neck training for medical students. He was Chairman of the Advanced Training Council for Head and Neck Oncology Fellowships in the USA for ten years and recipient of the Distinguished Service Award by the Head and Neck Society twice.

#### Selected Publications

**Shaha AR, Shah JP.** Completion thyroidectomy: fact or fiction? 2011 Am J Otolaryngol – Head and Neck Medicine and Surgery, 32 (5), p. 448-449.

Iyer NG, **Shaha AR.** Central compartment dissection for well differentiated thyroid cancer...and the band plays on. Curr Opin Otolaryngol Head Neck Surg. 2011; 19(2):106-12.

**Shaha AR, Shah JP.** Recurrent differentiated thyroid cancer. 2012 Endocr Pract. 18 (4) pp. 600-603. 2012 Jul 11:1-11

**Shaha AR.** Thyroid cancer and Delphian node. Eur Arch Otorhinolaryngol 2013 Apr 9 270 (9) pp. 2381-2382. (Epub ahead of print) No abstract available.

**Shaha AR.** Training of a thyroid surgeon: from scalpel to robot. Surgery 2012 Dec; 152 (6): Patel KN,

Patel KN, **Shaha AR.** Poorly differentiated thyroid cancer. Curr Opin Otolaryngol Head Neck Surg. 2014;22(2):121-6.

**Shaha AR.** Transaxillary thyroidectomy- A critical appraisal. J Surg Oncol. 2015 Feb; 111 (2): 131-2. No abstract available.

**Shaha AR.** Right paraesophageal lymph node metastasis. Eur J Surg Oncol. 2015 Nov 11. Epub ahead of print. No abstract available.

Cracchiolo JR, **Shaha AR.** Parotidectomy for Parotid Cancer. Otolaryngol Clin North Am. 2016 Apr; 49(2) 415-24. Epub 2016 Feb 17.

**Shaha AR.** Lobectomy vs total thyroidectomy - Have we resolved the debate? Int J Surg. 2017 Feb; 38:141-142. No abstract available.



## Valeria Silva Merea, MD

*Assistant Attending Surgeon  
Director, Speech and Hearing Center  
Memorial Sloan Kettering Cancer Center*

*Assistant Professor of Otolaryngology  
Weill Cornell Medical College*

**Education:** MD, Columbia University College of Physicians & Surgeons

**Residencies:** Otolaryngology-Head & Neck Surgery – NewYork-Presbyterian  
at Columbia Medical Center/Weill Cornell Medical Center

**Fellowships:** Laryngology – Cleveland Clinic



Valeria Silva Merea joined the Head and Neck Service in 2018. She is a laryngologist who specializes in caring for people with early laryngeal cancer, and voice, airway, and swallowing disorders. Managing these conditions sometimes requires a multidisciplinary approach, and Dr. Silva works closely with speech-language pathologists, her head and neck surgery colleagues, as well as other specialists such as interventional pulmonologists, gastroenterologists, thoracic surgeons, and radiation oncologists to provide the best care possible to her patients. As a laryngologist, she performs diagnostic and therapeutic in-office procedures, including vocal fold injection augmentations, KTP laser ablations, laryngeal steroid and botulinum toxin injections, as well as transnasal esophagoscopies.

Dr. Silva is particularly interested in the rehabilitation of voice and swallowing function in the cancer population, and she focuses on improving the patients' quality of life at this challenging time in their lives.

#### **Selected Publications**

**Silva Merea V**, Lee AHY, Peron DL, Waldman EH, Grunstein E. CPAS: Surgical approach with combined sublabial bone resection and inferior turbinate reduction without stents. *Laryngoscope*. 2015; 125(6): 1460-1464.

Dodhia S, **Silva Merea V**, Hibshoosh H, Nedumcheril M, Gudis DA, Rahmati R, Waldman EH. An unusual presentation of a rare soft tissue tumor in the tongue: Inflammatory myofibroblastic tumor. *Int J Pediatr Otorhinolaryngol Extra*. 2017; 15:1-3.

Cai Y, **Merea VS**, Lee AH, Su GH, Caruana SM. Nasopharyngeal papillomas treated with CO<sub>2</sub> laser and human papillomavirus vaccination. *Laryngoscope*. 2017; 127:2279-2281.

**Silva Merea V**, Husain S, Sulica L. Medialization laryngoplasty after injection augmentation. *J Voice*. 2018; 32:249-255.

**Silva Merea V**, Bryson PC. Office-based retrograde transtracheal application of mitomycin C. *Am J Otolaryngol*. 2018; 39:704-706.

Verma S, Yetzke M, **Silva Merea V**, Heye R, Clary M, Lott D, Bryson P. Are perioperative antibiotics necessary during direct microlaryngoscopy? *Laryngoscope*. 2018; 128:2838-2843.

Nelson R, Bryson P, **Silva Merea V**, Milstein C, Benninger M, Tierney W. Laryngeal botulinum toxin injection for vocal tremor: Utility of concurrent strap muscle injection. *Laryngoscope*. 2019; 129:1433-1437.

Lehman B, Procop GW, **Silva Merea V**, Harrington SM, Mawhorter S, Benninger MS. Chronic laryngitis caused by *Mycobacterium kansasii* in a traveler. *Laryngoscope*. 2019; 129:2534-2535.

**Silva Merea V**, Sadoughi B. Type I Posterior glottic stenosis: Natural history and in-office management. *Ann Otol Rhinol Laryngol*. 2019; 128:1073-1077.



## Bhuvanesh Singh, MD, PhD, FACS

*Attending Surgeon*  
*Director, Laboratory of Epithelial Cancer Biology*  
*Director, Speech and Hearing Center*  
Memorial Sloan Kettering Cancer Center

*Professor of Otolaryngology*  
Weill Cornell Medical College

**Education:** MD, SUNY Downstate College of Medicine  
PhD, Netherlands Cancer Institute, University of Amsterdam

**Residency:** SUNY Downstate Medical Center

**Fellowship:** Memorial Sloan Kettering Cancer Center



In addition to providing clinical care to patients with head and neck cancer, Bhuvanesh Singh helped to establish the Advanced Skin Cancer Management and Prevention Program at MSK. His laboratory focuses on the identification of novel approaches to treating head and neck cancer.

Dr. Singh's work was among the first to identify the significance of the PIK3CA/AKT pathway in head and neck and lung cancers. His laboratory also identified a novel gene, SCCRO, and revealed the gene as a major driver of the behavior of head and neck cancer, as well as many other human cancers. His team's findings have been validated by results and analysis performed by The Cancer Genome Atlas, not only in head and neck cancers, but also in lung, ovarian, cervical, and breast cancers. Having defined the biochemical function of SCCRO, Dr. Singh and his collaborators went on to complete a high-throughput screen and identified novel lead compounds, which they are now developing for use in human trials.

#### Selected Publications

Kutler DI, Wreesmann V, Goberdhan A, et al. Higher levels of human papilloma virus integration and lack of p53 mutations in squamous cell carcinoma from patients with Fanconi anemia. *J National Cancer Inst.* 2003;95:1718-21.

Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. *Genes Dev.* 2002;16:984-93.

Singh B, Gogineni SK, Sacks PG, et al. Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. *Cancer Res.* 2001;61:4506-13.

Sarkaria I, O-Charoenrat P, Talbot SG, et al. Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. *Cancer Research Oct.* 2006;66:9437-44.

Kim AY, Bommelje CC, Lee BE, et al. SCCRO (DCUN1D1) is an essential component of the E3 complex for neddylation. *J Biol Chem.* 2008;283:33211-20.

Bommelje CC, Weeda VB, Huang G, et al. Oncogenic function of SCCRO5/DCUN1D5 requires its neddylation E3 activity and nuclear localization. *Clin Cancer Res.* 2014;20:372-81.

Broderick SR, Golas BJ, Pham D, et al. SCCRO promotes glioma formation and malignant progression in mice. *Neoplasia.* 2010;12:476-84.

Huang G, Kaufman AJ, Ramanathan Y, Singh B. SCCRO (DCUN1D1) Promotes nuclear translocation and assembly of the neddylation E3 complex. *J Biol Chem.* 2011;286:10297-304.

Ganly I, Talbot S, Carlson D, et al. Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. *J Clin Oncol.* 2007;25:1369-76.

Wreesmann WB, Shi W, Thaler HT, et al. Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. *J Clin Oncol.* 2004;22:3965-72.



## Brian R. Untch, MD

*Assistant Attending Surgeon*  
Head and Neck Service  
Gastric and Mixed Tumor Service  
Memorial Sloan Kettering Cancer Center

*Assistant Professor of Surgery*  
Weill Cornell Medical College

**Education:** MD, Stritch School of Medicine

**Residency:** Duke University Medical Center

**Fellowship:** Memorial Sloan Kettering Cancer Center





Brian Untch is a board-certified surgeon who cares for patients with benign and cancerous endocrine and neuroendocrine (carcinoid) tumors. This includes diseases of the parathyroid, thyroid, adrenal glands and the gastrointestinal tract. Because these conditions are often complex, Dr. Untch works closely with colleagues in endocrinology, medical oncology, radiology, gastroenterology and pathology to deliver state-of-the-art multidisciplinary care. In addition to endocrine and neuroendocrine conditions, Dr. Untch also has a special interest in caring for patients with genetic and familial endocrine diseases including Multiple Endocrine Neoplasia (MEN) I, IIa, and IIb, von Hippel-Lindau Syndrome (VHL), paraganglioma syndromes, Cowden's Disease, familial hyperparathyroidism, familial medullary thyroid cancer, and Carney Complex.

Dr. Untch's research focuses on mechanisms of thyroid and neuroendocrine tumor progression and responses to therapy in the Human Oncology and Pathogenesis Program. Using genetically accurate models of cancer, he explores why certain tumors are more aggressive than others (such as poorly differentiated or anaplastic thyroid cancers) and how best to treat these with various interventions. Dr. Untch has been awarded multiple grants including those from the American Thyroid Association, the American Surgical Association, the Dana Foundation and the American Association of Endocrine Surgeons.

#### Selected Publications

Tang LH, Untch BR, Dhall D, Jih L, Reidy DL, O'Reilly EO, Vakiani E, Basturk O, Shia J, Sigel C, Allen PJ, Klimstra DS. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: A pathway distinct from poorly differentiated neuroendocrine carcinomas. *Clin Cancer Res* 2016; 15:1011-7.

Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Knauf JA, Smith V, Ganly I, Taylor B, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giaccotti F, Ghossein R and Fagin JA. NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition. *Cancer Disc* 2015; 5:1178-93.

Untch BR, Palmer F, Ganly I, Patel S, Tuttle R, Shah J, Shaha A. Oncologic outcomes after selective completion thyroidectomy for patients with well-differentiated thyroid carcinoma. *Ann Surg Oncol* 2014; 21:1374-8.

Untch BR, Gyorki DE, Tuttle MD, Shaha AR. Prophylactic central neck dissection in differentiated thyroid cancer – an assessment of the evidence. *Ann Surg Onc* 2013; 20:2285-9.

Untch BR, Adam MA, Scheri RP, Leight GS, Olson JA. Tumor proximity to the recurrent laryngeal nerve in patients undergoing surgery for primary hyperparathyroidism. *Ann Surg Oncol* 2012; 19: 3823-6.

Untch BR, Abdelgadir Adam M, Scheri RP, Leight GS, Olson JA. Surgeon-performed ultrasound is more accurate than 99Tc-sestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: Results in 516 patients over 10 years. *J Am Coll Surg* 2011;212:522-9.

Koh JJ, Dar M, Untch BR, Spurney RR, Dixit D, Marks JR, Dressman HK, Saito W, Olson JA Jr. Regulator of G-protein signaling 5 (RGS5) modulates human calcium sensing receptor and is variably expressed in primary hyperparathyroidism. *Mol Endo* 2011;25:867-76.

Abdelgadir Adam M, Untch BR, Danko ME, Stinnett S, Dixit D, Koh JJ, Marks JR, Olson JA Jr. Severe obesity is associated with greater symptoms, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. *J Clin Endocrinol Metab* 2010; 95:4917-24.

Abdelgadir Adam, M, Untch BR, Olson JA Jr. Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics. *Oncologist* 2010; 15:61-72.



## RECENT PUBLICATIONS BY MSK HEAD AND NECK SURGERY FELLOWS

### 2015

Roman BR, Patel SG, Wang MB, Pou AM, Holsinger FG, Myssiorek D, Goldenberg D, Swisher-McClure S, Lin A, Shah JP, Shea JA. Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer. *Jour Nat Compr Can Net*. 2015;13:69-77.

Wang LY, Palmer FL, Nixon IJ, Tuttle RM, Shah JP, Patel SG, Shaha AR, Ganly I. Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer. *Ann Surg Oncol*. 2015; (11):3530-6. doi: 10.1245/s10434-015-4398-2.

Wreesmann V, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, Shaha AR, Tuttle MM, Shah JP, Patel SG, Ghossein RA. Prognostic Value of Vascular Invasion in Well Differentiated Papillary Thyroid Carcinoma. *Thyroid*. 2015;25(5):503-8. doi: 10.1089/thy.2015.0052.

Dooley L, Shah J. Management of the neck in maxillary sinus carcinomas. *Curr Opin Otolaryngol Head Neck Surg*. 2015;23(2):107-14.

Iyer NG, Dogan S, Palmer F, Rahmati R, Nixon IJ, Lee N, Patel SG, Shah JP, Ganly I. Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic

Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer. *Ann Surg Oncol*. 2015. [Epub ahead of print]

Wang LY, Palmer FL, Migliacci JC, Nixon IJ, Shaha AR, Shah JP, Tuttle RM, Patel SG, Ganly I. Role of RAI in the management of incidental N1a disease in papillary thyroid cancer. *Clin Endocrinol (Oxf)*. 2015. [Epub ahead of print]

Wang LY, Ghossein R, Palmer FL, Nixon IJ, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I. Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. *Thyroid*. 2015;25(9):993-8. doi: 10.1089/thy.2015.0141.

Nixon IJ, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, Gönen M, Shah JP. Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. *Ann Surg Oncol*. 2015. [Epub ahead of print].

Wang LY, Roman BR, Migliacci JC, Palmer FL, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I. Cost-effectiveness analysis of papillary thyroid cancer surveillance. *Cancer*. 2015. [Epub ahead of print].

Mizrachi A, Swartzwelder CE, Shaha AR. Proposal for anatomical classification of the superior pole in thyroid surgery. *J Surg Oncol*. 2015;112(1):15-7. doi: 10.1002/jso.23950.

## 2016

- Cracchiolo JR, Shaha AR. Parotidectomy for Parotid Cancer. *Otolaryngol Clin North Am.* 2016;49(2):415-24.
- Cracchiolo JR, Baxi SS, Morris LG, Ganly I, Patel SG, Cohen MA, Roman BR. Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. *Cancer.* 2016;122(10):1523-32.
- Cohen WA, Albornoz CR, Cordeiro PG, Cracchiolo J, Encarnacion E, Lee M, Cavalli M, Patel S, Pusic AL, Matros E. Health-Related Quality of Life following Reconstruction for Common Head and Neck Surgical Defects. *Plast Reconstr Surg.* 2016;138(6):1312-1320.
- Cracchiolo JR, Roman BR, Kutler DI, Kuhel WI, Cohen MA. Adoption of transoral robotic surgery compared with other surgical modalities for treatment of oropharyngeal squamous cell carcinoma. *J Surg Oncol.* 2016;114(4):405-11.
- Mandal R, Şenbabaoglu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG. The head and neck cancer immune landscape and its immunotherapeutic implications. *JCI Insight.* 2016;1(17):e89829.
- Deborde S, Omelchenko T, Lyubchik A, Zhou Y, He S, McNamara WF, Chernichenko N, Lee SY, Barajas F, Chen CH, Bakst RL, Vakiani E, He S, Hall A, Wong RJ. Schwann cells induce cancer cell dispersion and invasion. *Clin Invest.* 2016;126(4):1538-54.
- Shkedy Y, Alkan U, Roman BR, Hilly O, Feinmesser R, Bachar G, Mizrahi A. Role of perioperative antibiotic treatment in parotid gland surgery. *Head Neck.* 2016;38:E1876-80.
- Mizrahi A, Shaha AR. Lymph Node Dissection for Differentiated Thyroid Cancer. *Mol Imaging Radionucl Ther.* 2016;26(Suppl 1):10-15.
- Mizrahi A, Shaha AR. In response to: Pay attention to EBSLN in anatomical classification of the superior pole in thyroid surgery. *J Surg Oncol.* 2016;114(3):394.
- Mandal R, Chan TA. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. *Cancer Discov.* 2016;6(7):703-13.
- Lennon P, Deady S, Healy ML, Toner M, Kinsella J, Timon CI, O'Neill JP. Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy. *Head Neck.* 2016;38 Suppl 1:E1122-9.
- Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, Gönen M, Carlson D, Ganly I, Shah JP, Ghossein R, Patel SG. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. *Head Neck.* 2016;38 Suppl 1:E1192-9.
- Givi B, Eskander A, Awad MI, Kong Q, Montero PH, Palmer FL, Xu W, De Almeida JR, Lee N, O'Sullivan B, Irish JC, Gilbert R, Ganly I, Patel SG, Goldstein DP, Morris LG. Impact of elective neck dissection on the outcome of oral squamous cell carcinomas arising in the maxillary alveolus and hard palate. *Head Neck.* 2016;38 Suppl 1:E1688-94.

## 2017

- Deborde S, Wong RJ. How Schwann cells facilitate cancer progression in nerves. *Cell Mol Life Sci.* 2017;74(24):4405-4420.
- Bakst RL, Xiong H, Chen CH, Deborde S, Lyubchik A, Zhou Y, He S, McNamara W, Lee SY, Olson OC, Leiner IM, Marcadis AR, Keith JW, Al-Ahmadie HA, Katabi N, Gil Z, Vakiani E, Joyce JA, Pamer E, Wong RJ. Inflammatory monocytes promote perineural invasion via CCL2-mediated recruitment and cathepsin B expression. *Cancer Res.* 2017;77(22):6400-6414.
- Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, Untch B, Ganly I, Shaha AR, Shah JP, Pace M, Li D, Back A, Lin O, Whiting A, Ghossein R, Landa I, Sabra M, Boucai L, Fish S, Morris LGT. Natural history of tumor volume kinetics of papillary thyroid cancers during active surveillance. *JAMA Otolaryngol Head Neck Surg.* 2017;143(10):1015-1050.
- Lin SF, Lin JD, Hsueh C, Chou TC, Wong RJ. Effects of ro niciclib in preclinical models of anaplastic thyroid cancer. *Oncotarget.* 2017;8(40):67990-68000.
- Lin SF, Lin JD, Hsueh C, Chou TC, Yen CN, Chen MH, Wong RJ. Efficacy of an HSP90 inhibitor, genetespi b, in preclinical thyroid cancer models. *Oncotarget.* 2017;8(25):41294-41304.
- Zanoni DK, Migliacci JC, Zu B, Katabi N, Montero PH, Ganly I, Shah JP, Wong RJ, Ghossein RA, Patel SG. A proposal to redefine close surgical margins in squamous cell carcinoma of the oral tongue. *JAMA Otolaryngol Head Neck Surg.* 2017;143(6):555-560.
- Hay A, Migliacci J, Karassawa Zanoni D, Boyle JO, Singh B, Wong RJ, Patel SG, Ganly I. Complications following transoral robotic surgery (TORS): A detailed institutional review of complications. *Oral Oncol.* 2017;67:160-166.
- Lin SF, Lin JD, Hsueh C, Chou TC, Wong RJ. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. *PLoS One.* 2017;12(2):e0172315.
- Sayed Z, Migliacci JC, Cracchiolo JR, Barker CA, Lee NY, McBride SM, Tabar VS, Ganly I, Patel SG, Morris LT, Roman BR, Shoushtari AN, Cohen MA. Association of surgical approach and margin status with oncologic outcomes following gross total resection for sinonasal melanoma. *JAMA Otolaryngol Head Neck Surg.* 2017;143(12):1220-1227.
- Cracchiolo JR, Patel K, Migliacci JC, Morris LT, Ganly I, Roman BR, McBride SM, Tabar VS, Cohen MA. Factors associated with a primary surgical approach for sinonasal squamous cell carcinoma. *J Surg Oncol.*
- Roman BR, Baxi SS, Cracchiolo JR, Blackwell TJ, Pfister DG, McBride S, Ganly I, Shah JP, Patel SG, Morris LG, Cohen MA. Variation in use of postoperative chemoradiation following surgery for T1 and T2 oropharyngeal squamous cell carcinoma; National Cancer Database. *J Surg Oncol.* 2017;116(3):351-358.
- Dalin MG, Katabi N, Persson M, Lee KW, Makarov V, Desrichard A, Walsh LA, West L, Nadeem Z, Ramaswami D, Havel JJ, Kuo F, Chadalavada K, Nanjangud GJ, Ganly I, Riaz N, Ho AL, Antonescu CR, Ghossein R, Stenman G, Chan TA, Morris LGT. Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. *Nat Commun.* 2017;8(1):1197.

Ibrahimasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, Deraje S, Carlson DL, Migliacci J, Knauf JA, Untch B, Berger MF, Morris L, Tuttle RM, Chan T, Fagin JA, Ghossein R, Ganly I. Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence. *Clin Cancer Res*. 2017;23(19):5970–5980.

Wang LY, Migliacci JC, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I. Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer. *Clin Endocrinol (Oxf)*. 2017;87(5):566–571.

Ali S, Palmer FL, Katabi N, Lee N, Shah JP, Patel SG, Ganly I. Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. *Laryngoscope*. 2017;127(10):2265–2269.

Shaha MA, Wang LY, Migliacci JC, Palmer FL, Nixon IJ, Tuttle RM, Shaha AR, Shah JP, Patel SG, Ganly I. Previous external beam radiation treatment exposure does not confer worse outcome for patients with differentiated thyroid cancer. *Thyroid*. 2017;27(3):412–417.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL Jr, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Wittek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines insights: head and neck cancers, version 2.2017. *J Natl Compr Canc Netw*. 2017;15(6):761–770.

Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM, Shah JP. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. *CA Cancer J Clin*. 2017;67(2):122–137.

Davies L, Morris L, Hankey B. Increases in thyroid cancer incidence and mortality. *JAMA*. 2017;318(4):389–390.

Roman BR, Morris LG, Davies L. The thyroid cancer epidemic, 2017 perspective. *Curr Opin Endocrinol Diabetes Obes*. 2017;24(5):332–336.

Davies L, Morris LGT. The USPSTF Recommendation on Thyroid Cancer Screening: Don't "Check Your Neck". *JAMA Otolaryngol Head Neck Surg*. 2017 Aug 1;143(8):755–756.

Dalin MG, Watson PA, Ho AL, Morris LG. Androgen receptor signaling in salivary gland cancer. *Cancers (Basel)*. 2017;9(2). pii:E17.

Roman BR, Yang A, Masciale J, Korenstein D. Association of attitudes regarding overuse of inpatient laboratory testing with health care provider type. *JAMA Intern Med*. 2017;177(8):1205–1207.

Shaha AR. Lobectomy vs total thyroidectomy - Have we resolved the debate? *Int J Surg*. 2017;38:141–142.

Huang G, Kaufman AJ, Xu K, Manova K, Singh B. Squamous cell carcinoma-related oncogene (SCCRO) neddylates Cul3 protein to selectively promote midbody localization and activity of Cul3(KLHL21) protein complex during abscission. *J Biol Chem*. 2017;292(37):15254–15265.

## 2019

Flukes S. Tonsillectomy complicated by jugular vein thrombosis and pulmonary embolism. *J Surg Case Rep*. 2018 Aug 15;2018(8):rjy202. doi: 10.1093/jscr/rjy202.

Boyle C, Asimakopoulos P, Khatamzas E, Vernham G. Mumps presenting with unilateral, synchronous parotid and submandibular gland swelling. *BMJ Case Rep*. 2018 Sep 4. pii: bcr-2018-226547. doi: 10.1136/bcr-2018-226547.

Asimakopoulos P, Thompson CSG, Hogg GE, Evans AS, Adamson RM, Vernham GA, Nixon IJ. Surgical and pathological outcomes of elective neck dissection during salvage total laryngectomy. *Clin Otolaryngol*. 2019 May;44(3):375–378. doi: 10.1111/coa.13266.

Wu JX. Rebuilding trust in the surgeon-patient relationship: Need for transparency. *Acad Med*. 2019 May;94(5):614–615. doi: 10.1097/ACM.0000000000002632.

Asimakopoulos P, Charalampidis G, Chakravarthy KM, Mamais C. Ten years of ENT Scotland meetings: an appraisal of the publication rates of trainee-presented scientific papers. *J Laryngol Otol*. 2019 Jun;133(6):526–529. doi: 10.1017/S0022215119001075.

Flukes S, Garry S, Hinton-Bayre A, Lindsay A. Pre-treatment wait time for head and neck cancer patients in Western Australia: Description of a new metric and examination of predictive factors. *ANZ J Surg*. 2019 Jul;89(7-8):858–862. doi: 10.1111/ans.14860.

Hanson MA, Shaha AR, Wu JX. Surgical approach to the substernal goiter. *Best Pract Res Clin Endocrinol Metab*. 2019 Aug;33(4):101312. doi: 10.1016/j.beem.2019.101312. *Review*.

Wu JX, Hanson M, Shaha AR. Sentinel node biopsy for cancer of the oral cavity. *J Surg Oncol*. 2019 Aug;120(2):99–100. doi: 10.1002/jso.25493.

Mimica X, Hanson M, Patel SG, McGill M, McBride S, Lee N, Dunn LA, Cracchiolo JR, Shah JP, Wong RJ, Ganly I, Cohen MA. Salvage surgery for recurrent larynx cancer. *Head Neck*. 2019 Nov;41(11):3906–3915. doi: 10.1002/hed.25925.

Tan AL, Iyer NG, Putri N, Nadkarni N, Skanthakumar T, Wong TH, Tay GCA. Factors driving frequent attendance at emergency departments for patients with head and neck cancer. *Head Neck*. 2019 Nov;41(11):3798–3805. doi: 10.1002/hed.25916.

Wu JX, Assel M, Vickers A, Afonso AM, Twersky RS, Simon BA, Cohen MA, Rieth EF, Cracchiolo JR. Impact of intraoperative remifentanyl on postoperative pain and opioid use in thyroid surgery. *J Surg Oncol*. 2019 Dec;120(8):1456–1461. doi: 10.1002/jso.25746.

**HEAD AND NECK SERVICE ALUMNI  
(1979-2019)**



1979-1980	Richard A. Lopchinsky General Surgery, Phoenix, AZ	1988-1989	Thomas R. Loree Otolaryngology/Surgery, Sisters of Charity Hospital, Buffalo, NY
1980-1981	Gaetano DeRose General Surgery, London Health Sciences, London, ON, Canada	1989-1990	Sanford Dubner Head and Neck Surgery, North Shore LIJ, New Hyde Park, NY
1981-1982	Ashok R. Shaha Attending Surgeon, Head and Neck Service, MSK, New York, NY	1990-1991	Dennis Kraus Director of the New York Head and Neck Institute, North Shore LIJ, New York, NY
1982-1983	Walter King Director, Plastic and Reconstructive Surgery, Santitorium Hospital, Hong Kong	1991-1992	Mark DeLacure Associate Professor, Otolaryngology, NYU Langone Medical Center, New York, NY
1983-1984	Larry Sheman ENT, Private Practice, New York, NY	1992-1994	Bruce Davidson Professor and Chair, Otolaryngology, Georgetown University, Washington DC
1984-1985	Barry Wenig Director of the Head and Neck Surgery Center, University of Illinois, Chicago, IL	1993-1994	Christopher Hughes Consultant Head and Neck Surgeon, St. Vincent's Hospital, Sydney, Australia
1985-1986	Robert T. Parrish ENT, Midwest ENT Associates, Peoria, IL	1993-1995	Peter Andersen Otolaryngology, OHSU, Portland, OR
1986-1988	Soo Khee Chee Director of the National Cancer Center of Singapore	1993-1995	William Lydiatt Director, Head and Neck Surgery, Vice Chair, Otolaryngology, University of Nebraska, Omaha, NE
1987-1988	Jeffrey Spiro ENT, University of Connecticut, Farmington CT		

1994-1996	Daniel Kelley ENT Private Practice, Salisbury, MD	2003-2005	Ian Ganly Associate Attending Surgeon, Head and Neck Service, MSK, New York, NY
1995-1996	Gary Morgan Clinical Associate Professor, University of Sydney, Australia	2002-2005	Neil Gross Head and Neck Surgeon, MD Anderson Cancer Center, Houston, TX
1996-1997	Paul Friedlander Associate Professor and Chair of Otolaryngology, Tulane University, New Orleans, LA	2003-2005	Susan McCammon Associate Professor of Otolaryngology, University of Texas Medical Branch, League City, TX
1995-1997	Sal Caruana Otolaryngology, New York Presbyterian, Columbia and Cornell, New York, NY	2005-2007	Jennifer Bocker Head and Neck Surgery Private Practice, Golden, CO
1996-1998	Dennis Teck-Hock Lim Head and Neck Surgeon, Private Practice, Mt. Elizabeth Hospital, Singapore	2007-2009	Jerry Castro ENT, Guam Memorial Hospital, Tamuning, Guam
1997-1998	Anthony Tufaro Vice Chair of Plastic Surgery, Johns Hopkins Medical Center, Baltimore, MD	2008-2009	Silvio Ghirardo Attending Surgeon, Mercy Medical Center, Cedar Rapids, IA
1996-1998	Jay O. Boyle Associate Attending Surgeon, Head and Neck Service, MSK, New York, NY	2007-2009	Vincent Reid Attending Surgeon, Mercy Medical Center, Cedar Rapids, IA
1997-1999	John Carew Otolaryngology Head and Neck Surgery, Private Practice, New York, NY	2006-2008	Vishal Choksi Chief of Head and Neck Surgery, Apollo Hospitals, Ahmedbad, India
1997-1999	Bhuvanesh Singh Attending Surgeon, Head and Neck Service, MSK, New York, NY	2006-2008	Ziv Gil Chairman, Otolaryngology, Rambam Medical Center, Haifa, Israel
1998-2000	Paul Kodeshian Head and Neck Surgeon, Ronald Reagan UCLA Medical Center, Santa Monica, CA	2007-2008	Patrick Sheahan Consultant Otolaryngologist, South Infirmery Victoria University Hospital, Cork, Ireland
1998-2000	Snehal G. Patel Attending Surgeon, Head and Neck Service, MSK, New York, NY	2007-2009	Benjamin Judson Assistant Professor of Otolaryngology, Yale School of Medicine, New Haven, CT
1999-2000	Joseph Califano Director, Head and Neck Cancer Center, UC San Diego, CA	2007-2010	Daniel Price Assistant Professor of Otolaryngology, Mayo Clinic, Rochester, MN
1999-2001	Richard J. Wong Chief, Head and Neck Service, MSK, New York, NY	2007-2009	Ben Saltman Assistant Professor of Otolaryngology, North Shore LIJ, New Hyde Park, NY
2000-2003	Brandon G. Bentz Otolaryngology, Salt Lake City, UT	2008-2009	Nishant Agrawal Chief Head and Neck Surgery, University of Chicago, Chicago, IL
2001-2002	Maria Evasovich Surgical Oncologist, University of Minnesota Medical Center, Minneapolis, MN	2008-2009	Hin Ngan Tay Otolaryngologist, Head and Neck Surgeon, Mt. Elizabeth Hospital, Singapore
2002-2003	Erik Cohen Director of Head and Neck Surgery, Morristown Medical Center, Morristown, NJ	2008-2010	Babak Givi Assistant Professor of Otolaryngology, NYU Langone Medical Center, New York, NY
2001-2004	David Kutler Associate Attending, New York Presbyterian, Cornell University, New York, NY	2008-2010	Jeffrey Liu Assistant Professor of Otolaryngology, Temple University, Philadelphia, PA
2002-2004	Ellie Maghami Chief, Head and Neck Surgery, City of Hope, Duarte, CA	2009-2010	Arnbjorn Toset General Surgery, Private Practice, Long Island, NY
2003-2004	Kepal Patel Chief, Division of Endocrine Surgery, NYU Langone Medical Center, New York, NY	2011-2012	Iain Nixon Head and Neck Surgeon, NHS Lothian and Edinburgh University, Edinburgh, United Kingdom

2009-2010	Gopal Iyer Chief Head and Neck Surgery Singapore General Hospital, Singapore	2014-2016	Aviram Mizrachi Rabin Medical Center, Petah Tikva, Israel
2010-2011	Arash Mohebati General Surgery, John Muir Health, Walnut Creek, CA	2016 – 2017	Jennifer Cracchiolo Assistant Attending Surgeon, Head and Neck Service MSK, New York, NY
2009-2011	Luc Morris Assistant Attending Surgeon, Head and Neck Service, MSK, New York, NY	2016 – 2017	Navin Mani Consultant Head and Neck Surgeon, Manchester Royal Infirmary/The Christie Hospital Manchester, UK
2010-2011	Rahmatullah Rahmati Assistant Professor, New York Presbyterian, Columbia University, New York, NY	2016 – 2017	Julianna Pesce Head and Neck Surgeon, Westside Head and Neck Culver City, CA
2010-2011	James Paul O'Neill Professor of Otolaryngology, Royal College of Surgeons in Ireland, Dublin, Ireland	2016 – 2017	Zafar Sayed Attending Physician, University of Nebraska Omaha, NE
2011-2013	Volkert Wreesmann Head and Neck Surgeon, Netherlands Cancer Institute, Amsterdam, The Netherlands	2017-2018	Sundeep Alapati Otolaryngologist, Jacobi Medical Center, Bronx NY
2010-2012	Natalya Chernichenko Chief of Head and Neck Surgery, SUNY Downstate Medical Center, Brooklyn, NY	2017-2018	Serena Byrd Head and Neck Surgeon, Summit Medical Group Florham Park NJ
2011-2014	Allen Ho Director of Head and Neck Oncology Cedars-Sinai Medical Center, Los Angeles, CA	2017-2018	Benzon Dy Assistant Professor of Endocrine Surgery, Mayo Clinic Rochester MN
2011-2013	Andrew G. Shuman Assistant Professor of Otolaryngology, University of Michigan, Ann Arbor, MI	2017-2018	Ashley Hay Otolaryngologist, NHS Lothian, Edinburgh, Scotland
2012-2014	Mina Le Otolaryngology, West Palm Beach VA Medical Center, Riviera Beach, FL	2017-2018	Julie Kickbush Head and Neck Surgeon, CancerCare Manitoba, Winnipeg, Canada
2012-2014	William McNamara General Surgery, Medical City Hospital, Dallas, TX	2017-2018	Rajarsi Mandal Assistant Professor of Otolaryngology, Johns Hopkins University, Baltimore, MD
2012-2015	Benjamin R. Roman Assistant Attending Surgeon, Head and Neck Service, MSK, New York, NY	2017-2018	Rachel Giese Otolaryngologist, University of Texas Rio Grande Valley, Edinburg TX
2013-2014	Yamil Castillo-Beauchamp Head and Neck Surgery, San Juan, Puerto Rico	2018-2019	James Wu Endocrine Surgeon, UCLA Health Los Angeles, CA
2013-2015	Pablo Montero Miranda Head and Neck Surgery, University Hospital, Santiago, Chile	2018-2019	Shivangi Lohia Research Associate Head and Neck Service, MSK New York NY
2012-2015	Andres Lopez-Albaitero ENT, Private Practice, New York, NY	2018-2019	Laura Wang Surgical Fellow, Plastic and Reconstructive Surgery Service, MSK New York, NY
2013-2015	Laura M. Dooley Assistant Professor of Otolaryngology, University of Missouri School of Medicine, Columbia, MO	2018-2019	Martin Hanson Instructor, UVA Health System Charlottesville, VA
2015 - 2016	Gregory Beddell Western Reserve Hospital, Stow, OH	2018-2019	Hao Li Visiting Consultant Head and Neck Surgeon, National University Health System, Singapore
2015-2016	Paul Lennon St. James's Hospital, Dublin, Ireland		
2015-2016	Magis Mandapathil University of Marburg, Marburg, Germany		



## Memorial Sloan Kettering Cancer Center

**Head and Neck Oncologic Surgery  
Fellowship Program**

1275 York Avenue  
New York, NY 10065  
[www.mskcc.org](http://www.mskcc.org)

**Department of Surgery  
Education Program**

T 212-639-7537  
F 212-717-3169  
[surfellowships@mskcc.org](mailto:surfellowships@mskcc.org)